A Significant Step Forward in Ovarian Cancer Research Oncoinvent AS, a clinical-stage radiopharmaceutical company, has announced a major achievement in its ongoing clinical development program. The company has officially reached the 50% recruitment milestone in its Phase 2a clinical trial evaluating Radspherin®, a novel alpha-emitting radioactive microsphere treatment designed for patients with advanced ovarian cancer.…